Regeneron Pharmaceuticals, Inc. (REGN)
828.72
-5.32
(-0.64%)
USD |
NASDAQ |
Aug 24, 16:00
834.55
+5.83
(+0.70%)
After-Hours: 20:00
Regeneron Pharmaceuticals Enterprise Value : 80.94B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 80.94B |
| August 20, 2026 | 80.18B |
| August 19, 2026 | 81.64B |
| August 18, 2026 | 78.48B |
| August 17, 2026 | 78.03B |
| August 14, 2026 | 77.78B |
| August 13, 2026 | 78.04B |
| August 12, 2026 | 77.21B |
| August 11, 2026 | 77.11B |
| August 10, 2026 | 78.25B |
| August 07, 2026 | 75.80B |
| August 06, 2026 | 74.54B |
| August 05, 2026 | 74.17B |
| August 04, 2026 | 73.35B |
| August 03, 2026 | 73.21B |
| July 31, 2026 | 73.56B |
| July 30, 2026 | 71.05B |
| July 29, 2026 | 66.61B |
| July 28, 2026 | 66.58B |
| July 27, 2026 | 63.69B |
| July 24, 2026 | 62.53B |
| July 23, 2026 | 62.11B |
| July 22, 2026 | 62.03B |
| July 21, 2026 | 64.52B |
| July 20, 2026 | 64.20B |
| Date | Value |
|---|---|
| July 17, 2026 | 64.67B |
| July 16, 2026 | 64.90B |
| July 15, 2026 | 63.41B |
| July 14, 2026 | 62.54B |
| July 13, 2026 | 63.27B |
| July 10, 2026 | 63.41B |
| July 09, 2026 | 63.77B |
| July 08, 2026 | 63.24B |
| July 07, 2026 | 64.62B |
| July 06, 2026 | 61.89B |
| July 02, 2026 | 62.35B |
| July 01, 2026 | 59.30B |
| June 30, 2026 | 59.18B |
| June 29, 2026 | 60.28B |
| June 26, 2026 | 60.40B |
| June 25, 2026 | 59.06B |
| June 24, 2026 | 59.40B |
| June 23, 2026 | 58.84B |
| June 22, 2026 | 58.26B |
| June 18, 2026 | 57.99B |
| June 17, 2026 | 57.78B |
| June 16, 2026 | 58.49B |
| June 15, 2026 | 58.52B |
| June 12, 2026 | 58.22B |
| June 11, 2026 | 58.15B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Gilead Sciences, Inc. | 202.61B |
| AbbVie, Inc. | 532.50B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| Amgen, Inc. | 280.82B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.297B |
| Revenue (Quarterly) | 4.291B |
| Total Expenses (Quarterly) | 2.994B |
| EPS Diluted (Quarterly) | 12.23 |
| Gross Profit Margin (Quarterly) | 83.68% |
| Profit Margin (Quarterly) | 30.23% |
| Earnings Yield | 4.88% |
| Operating Earnings Yield | 4.70% |
| Normalized Earnings Yield | 5.176 |